Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Neurocrine Gains Clinical-Stage Schizophrenia Candidates Returned To Sosei By AbbVie

Executive Summary

Deal Snapshot: Neurocrine expanded its pipeline with rights to subtype-selective muscarinic M4, M1 and dual M1/M4 receptor agonists discovered by Sosei.

You may also be interested in...



Sosei Bolsters GPCR Focus With AbbVie Neurology Deal

The Japanese firm has expanded its partnership with AbbVie into the neurology space, where it hopes to use its unique platform technology to develop up to three drug candidates targeting ‘challenging’ G protein-coupled receptor targets.

Return Of In-Person Psychiatry Visits Could Lift Neurocrine’s Ingrezza

Ingrezza became a $1bn therapy in 2022 despite the pandemic, but Neurocrine expect many more patients are diagnosed and treated if the pandemic eases as hoped.

Neurocrine Closer To Ingrezza Label Expansion With Huntington’s Chorea Phase III Win

The neuroscience-focused firm plans a 2022 supplemental NDA for Ingrezza following success in the pivotal KINECT-HD study. The biotech needed an R&D success after recent stumbles.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145453

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel